Compare Regeneron Pharmaceuticals Inc (REGN) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ProShares UltraPro S&P500 — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while ProShares UltraPro S&P500 trades at $141.2. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | UPRO | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $812.27 | $150.93 |
52-Week Low | $545.46 | $89.29 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
UPRO trades at $138.50, down 0.4% on the day, with technical indicators showing a bearish bias as the stock faces resistance near $140-141 levels. The overall technical signal is bearish with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights broader S&P 500 concerns about valuation levels and market concentration in tech stocks, creating headwinds for leveraged ETFs like UPRO.
The outlook for UPRO remains challenged by elevated market valuations and technical resistance. Investment opportunity exists if the S&P 500 breaks through current resistance levels, but risks include continued market volatility and potential mean reversion in tech-heavy indices. The bearish technical setup suggests caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
